Eli Lilly: Credit Suisse inches up target price
(CercleFinance.com) - Credit Suisse has raised its target price on Eli Lilly from 82 dollars to 84 dollars, but maintains its "underperform" rating on the stock, after its steady recovery over recent weeks, following a period of underperformance earlier this year.
While the broker acknowledges that there are reasons for increased optimism in the diabetes and non-diabetes parts of the business, it remains cautious ahead of the results of a trial investigating cardiovascular events with a weekly incretin in diabetes.
Indeed, Credit Suisse believes the study may not be able to prove superiority in reducing cardiovascular events.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
While the broker acknowledges that there are reasons for increased optimism in the diabetes and non-diabetes parts of the business, it remains cautious ahead of the results of a trial investigating cardiovascular events with a weekly incretin in diabetes.
Indeed, Credit Suisse believes the study may not be able to prove superiority in reducing cardiovascular events.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.